Association of serum docosahexaenoic acid with cerebral amyloidosis

Hussein N. Yassine, Qingru Feng, Ida Azizkhanian, Varun Rawat, Katherine Castor, Alfred N. Fonteh, Michael G. Harrington, Ling Zheng, Bruce R Reed, Charles DeCarli, William J. Jagust, Helena C. Chui

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Importance Higher dietary intake of the essential fatty acid docosahexaenoic (DHA) has been associated with better cognitive performance in several epidemiological studies. Animal and in vitro studies also indicate that DHA prevents amyloid deposition in the brain. OBJECTIVE To determine the association between serum DHA levels, cerebral amyloidosis, and the volumes of brain areas affected by Alzheimer disease. DESIGN, SETTINGS, AND PARTICIPANTS Cross-sectional analysis of serum DHA levels together with measures of amyloid deposition (Pittsburgh Compound B index), brain volumes, and neuropsychological testing scores from 61 participants in the Aging Brain Study. The study was conducted between June 2008 and May 2013, and the data were analyzed between October 2015 and April 2016. Linear models were adjusted for age, sex, years of education, and apolipoprotein E status. MAIN OUTCOMES AND MEASURES Serum DHA levels with cerebral amyloidosis measured using PIB PET. RESULTS Samples were available from 61 Aging Brain Study participants (41 women and 20 men) who underwent amyloid PET imaging. The mean (SD) age of the participants was 77 (6) years and ranged from 67 to 88 years. Serum DHA levels (percentage of total fatty acids) were 23% lower in participants with cerebral amyloidosis than those without (0.97 vs 1.25, P =.007) and were inversely correlated with brain amyloid load (r =-0.32, P =.01) independent of age, sex, apolipoprotein E genotype, and years of education. Moreover, greater serum DHA levels were positively associated with brain volume in several subregions affected by AD, in particular the left subiculum (r = 0.38, P =.005) and the left entorhinal volumes (r = 0.51, P =.001). Serum DHA levels were also associated with nonverbal memory scores (r = 0.28, P =.03). CONCLUSIONS AND RELEVANCE In this study, serum DHA levels were associated with pathogenesis of cerebral amyloidosis and with preservation of entorhinal and hippocampal volumes. These findings suggest an important role for DHA metabolism in brain amyloid deposition during the preclinical or early symptomatic stages of Alzheimer disease.

Original languageEnglish (US)
Pages (from-to)1208-1216
Number of pages9
JournalJAMA Neurology
Volume73
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Docosahexaenoic Acids
Amyloid
Brain
Serum
Apolipoproteins E
Alzheimer Disease
Essential Fatty Acids
Sex Education
Amyloid angiopathy
Epidemiologic Studies
Linear Models
Hippocampus
Fatty Acids
Cross-Sectional Studies
Genotype
Education

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Yassine, H. N., Feng, Q., Azizkhanian, I., Rawat, V., Castor, K., Fonteh, A. N., ... Chui, H. C. (2016). Association of serum docosahexaenoic acid with cerebral amyloidosis. JAMA Neurology, 73(10), 1208-1216. https://doi.org/10.1001/jamaneurol.2016.1924

Association of serum docosahexaenoic acid with cerebral amyloidosis. / Yassine, Hussein N.; Feng, Qingru; Azizkhanian, Ida; Rawat, Varun; Castor, Katherine; Fonteh, Alfred N.; Harrington, Michael G.; Zheng, Ling; Reed, Bruce R; DeCarli, Charles; Jagust, William J.; Chui, Helena C.

In: JAMA Neurology, Vol. 73, No. 10, 01.10.2016, p. 1208-1216.

Research output: Contribution to journalArticle

Yassine, HN, Feng, Q, Azizkhanian, I, Rawat, V, Castor, K, Fonteh, AN, Harrington, MG, Zheng, L, Reed, BR, DeCarli, C, Jagust, WJ & Chui, HC 2016, 'Association of serum docosahexaenoic acid with cerebral amyloidosis', JAMA Neurology, vol. 73, no. 10, pp. 1208-1216. https://doi.org/10.1001/jamaneurol.2016.1924
Yassine HN, Feng Q, Azizkhanian I, Rawat V, Castor K, Fonteh AN et al. Association of serum docosahexaenoic acid with cerebral amyloidosis. JAMA Neurology. 2016 Oct 1;73(10):1208-1216. https://doi.org/10.1001/jamaneurol.2016.1924
Yassine, Hussein N. ; Feng, Qingru ; Azizkhanian, Ida ; Rawat, Varun ; Castor, Katherine ; Fonteh, Alfred N. ; Harrington, Michael G. ; Zheng, Ling ; Reed, Bruce R ; DeCarli, Charles ; Jagust, William J. ; Chui, Helena C. / Association of serum docosahexaenoic acid with cerebral amyloidosis. In: JAMA Neurology. 2016 ; Vol. 73, No. 10. pp. 1208-1216.
@article{b7d1ac4035554cb589cb37ab11c6ee4c,
title = "Association of serum docosahexaenoic acid with cerebral amyloidosis",
abstract = "Importance Higher dietary intake of the essential fatty acid docosahexaenoic (DHA) has been associated with better cognitive performance in several epidemiological studies. Animal and in vitro studies also indicate that DHA prevents amyloid deposition in the brain. OBJECTIVE To determine the association between serum DHA levels, cerebral amyloidosis, and the volumes of brain areas affected by Alzheimer disease. DESIGN, SETTINGS, AND PARTICIPANTS Cross-sectional analysis of serum DHA levels together with measures of amyloid deposition (Pittsburgh Compound B index), brain volumes, and neuropsychological testing scores from 61 participants in the Aging Brain Study. The study was conducted between June 2008 and May 2013, and the data were analyzed between October 2015 and April 2016. Linear models were adjusted for age, sex, years of education, and apolipoprotein E status. MAIN OUTCOMES AND MEASURES Serum DHA levels with cerebral amyloidosis measured using PIB PET. RESULTS Samples were available from 61 Aging Brain Study participants (41 women and 20 men) who underwent amyloid PET imaging. The mean (SD) age of the participants was 77 (6) years and ranged from 67 to 88 years. Serum DHA levels (percentage of total fatty acids) were 23{\%} lower in participants with cerebral amyloidosis than those without (0.97 vs 1.25, P =.007) and were inversely correlated with brain amyloid load (r =-0.32, P =.01) independent of age, sex, apolipoprotein E genotype, and years of education. Moreover, greater serum DHA levels were positively associated with brain volume in several subregions affected by AD, in particular the left subiculum (r = 0.38, P =.005) and the left entorhinal volumes (r = 0.51, P =.001). Serum DHA levels were also associated with nonverbal memory scores (r = 0.28, P =.03). CONCLUSIONS AND RELEVANCE In this study, serum DHA levels were associated with pathogenesis of cerebral amyloidosis and with preservation of entorhinal and hippocampal volumes. These findings suggest an important role for DHA metabolism in brain amyloid deposition during the preclinical or early symptomatic stages of Alzheimer disease.",
author = "Yassine, {Hussein N.} and Qingru Feng and Ida Azizkhanian and Varun Rawat and Katherine Castor and Fonteh, {Alfred N.} and Harrington, {Michael G.} and Ling Zheng and Reed, {Bruce R} and Charles DeCarli and Jagust, {William J.} and Chui, {Helena C.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1001/jamaneurol.2016.1924",
language = "English (US)",
volume = "73",
pages = "1208--1216",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Association of serum docosahexaenoic acid with cerebral amyloidosis

AU - Yassine, Hussein N.

AU - Feng, Qingru

AU - Azizkhanian, Ida

AU - Rawat, Varun

AU - Castor, Katherine

AU - Fonteh, Alfred N.

AU - Harrington, Michael G.

AU - Zheng, Ling

AU - Reed, Bruce R

AU - DeCarli, Charles

AU - Jagust, William J.

AU - Chui, Helena C.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Importance Higher dietary intake of the essential fatty acid docosahexaenoic (DHA) has been associated with better cognitive performance in several epidemiological studies. Animal and in vitro studies also indicate that DHA prevents amyloid deposition in the brain. OBJECTIVE To determine the association between serum DHA levels, cerebral amyloidosis, and the volumes of brain areas affected by Alzheimer disease. DESIGN, SETTINGS, AND PARTICIPANTS Cross-sectional analysis of serum DHA levels together with measures of amyloid deposition (Pittsburgh Compound B index), brain volumes, and neuropsychological testing scores from 61 participants in the Aging Brain Study. The study was conducted between June 2008 and May 2013, and the data were analyzed between October 2015 and April 2016. Linear models were adjusted for age, sex, years of education, and apolipoprotein E status. MAIN OUTCOMES AND MEASURES Serum DHA levels with cerebral amyloidosis measured using PIB PET. RESULTS Samples were available from 61 Aging Brain Study participants (41 women and 20 men) who underwent amyloid PET imaging. The mean (SD) age of the participants was 77 (6) years and ranged from 67 to 88 years. Serum DHA levels (percentage of total fatty acids) were 23% lower in participants with cerebral amyloidosis than those without (0.97 vs 1.25, P =.007) and were inversely correlated with brain amyloid load (r =-0.32, P =.01) independent of age, sex, apolipoprotein E genotype, and years of education. Moreover, greater serum DHA levels were positively associated with brain volume in several subregions affected by AD, in particular the left subiculum (r = 0.38, P =.005) and the left entorhinal volumes (r = 0.51, P =.001). Serum DHA levels were also associated with nonverbal memory scores (r = 0.28, P =.03). CONCLUSIONS AND RELEVANCE In this study, serum DHA levels were associated with pathogenesis of cerebral amyloidosis and with preservation of entorhinal and hippocampal volumes. These findings suggest an important role for DHA metabolism in brain amyloid deposition during the preclinical or early symptomatic stages of Alzheimer disease.

AB - Importance Higher dietary intake of the essential fatty acid docosahexaenoic (DHA) has been associated with better cognitive performance in several epidemiological studies. Animal and in vitro studies also indicate that DHA prevents amyloid deposition in the brain. OBJECTIVE To determine the association between serum DHA levels, cerebral amyloidosis, and the volumes of brain areas affected by Alzheimer disease. DESIGN, SETTINGS, AND PARTICIPANTS Cross-sectional analysis of serum DHA levels together with measures of amyloid deposition (Pittsburgh Compound B index), brain volumes, and neuropsychological testing scores from 61 participants in the Aging Brain Study. The study was conducted between June 2008 and May 2013, and the data were analyzed between October 2015 and April 2016. Linear models were adjusted for age, sex, years of education, and apolipoprotein E status. MAIN OUTCOMES AND MEASURES Serum DHA levels with cerebral amyloidosis measured using PIB PET. RESULTS Samples were available from 61 Aging Brain Study participants (41 women and 20 men) who underwent amyloid PET imaging. The mean (SD) age of the participants was 77 (6) years and ranged from 67 to 88 years. Serum DHA levels (percentage of total fatty acids) were 23% lower in participants with cerebral amyloidosis than those without (0.97 vs 1.25, P =.007) and were inversely correlated with brain amyloid load (r =-0.32, P =.01) independent of age, sex, apolipoprotein E genotype, and years of education. Moreover, greater serum DHA levels were positively associated with brain volume in several subregions affected by AD, in particular the left subiculum (r = 0.38, P =.005) and the left entorhinal volumes (r = 0.51, P =.001). Serum DHA levels were also associated with nonverbal memory scores (r = 0.28, P =.03). CONCLUSIONS AND RELEVANCE In this study, serum DHA levels were associated with pathogenesis of cerebral amyloidosis and with preservation of entorhinal and hippocampal volumes. These findings suggest an important role for DHA metabolism in brain amyloid deposition during the preclinical or early symptomatic stages of Alzheimer disease.

UR - http://www.scopus.com/inward/record.url?scp=84998706975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998706975&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2016.1924

DO - 10.1001/jamaneurol.2016.1924

M3 - Article

C2 - 27532692

AN - SCOPUS:84998706975

VL - 73

SP - 1208

EP - 1216

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 10

ER -